Shorla Oncology
Founded 2018 · 35 employees on LinkedIn · 4 known investors
Shorla Oncology develops and commercializes oncology drugs for indications where existing treatments are limited, in shortage, or inadequate for the target population. Its portfolio focuses on niche cancer treatments aimed at improving patient access and affordability.
Investors · 4
Kurma PartnersParis · $162K – $10.8M
Seroba Life SciencesDublin · $540K – $7.6M
Enterprise IrelandreportedDublin
Also in the syndicate · 1
Kurma Partners' Growth Opportunities Fundlead
Funding
SEC filings, press & company announcements$35M disclosed across 1 of 3 rounds · 2023
- $35MSeries BOct 2023 · 2 sources
Kurma Partners' Growth Opportunities Fund (lead), Enterprise Ireland, Seroba Life Sciences
Source ↗ - Undisclosed amountSeries-BOct 2023Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Shorla Oncology do?
- Shorla Oncology develops and commercializes oncology drugs for indications where existing treatments are limited, in shortage, or inadequate for the target population. Its portfolio focuses on niche cancer treatments aimed at improving patient access and affordability.
- Who are Shorla Oncology's investors?
- Shorla Oncology's investors include Kurma Partners, Seroba Life Sciences, Enterprise Ireland.
- How much funding has Shorla Oncology raised?
- Shorla Oncology has disclosed $35M raised across 1 of its 3 known rounds.